NTK Institute Logo Mission Statement - Dedicated to improving medical practice through the immediate delivery of new clinically-relevant science to physicians who most urgently need to know about this science Need-To-Know Science Scoring System
About The Institute
NTK Initiative
NTK Watch
Recently Scored Science
Contact Us
To sign up to receive the NTK Watch daily e-mail
All alendronate News
02/06/2015 Bisphosphonate-related osteonecrosis of the palatal torus (ORL, Journal of Oto-Rhino-Laryngology and Its Related Specialties)
01/29/2015 Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis (Osteoporos Int)
01/14/2015 Treatment of primary osteoporosis in men (Clin Interv Aging)
12/31/2014 Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover (Aging Clin Exp Res)
12/16/2014 Current and future treatments of osteoporosis in men (Best Pract Res Clin Endocrinol Metab)
12/04/2014 Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference (J Endocrinol Invest)
11/19/2014 Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures (Clin Rheumatol)
10/30/2014 Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches (Curr Osteoporos Rep)
10/21/2014 Bisphosphonate-Induced Cutaneous Adverse Events: The Difficulty of Assessing Imputability through Patch Testing (Dermatology)
10/20/2014 Is There Enough Evidence to Use Bisphosphonates in HIV-Infected Patients? A Systematic Review and Meta-analysis (AIDS Rev)
08/19/2014 Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer: Results From the Randomized Clinical Trials of Alendronate and Zoledronic Acid (JAMA Intern Med)
07/07/2014 The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment (Aging Clin Exp Res)
05/30/2014 Incidence and Risk of Venous Thromboembolism Among Taiwan Osteoporotic Fracture Population under Osteoporosis Pharmacological Treatments (J Clin Endocrinol Metab)
05/13/2014 Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy: The FLEX Study (JAMA Intern Med)
05/06/2014 Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials (J Bone Miner Metab)
04/29/2014 Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis (Osteoporos Int)
04/17/2014 The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate (Bone)
04/11/2014 Fracture Risk Reduction with Denosumab in Japanese Postmenopausal Women and Men with Osteoporosis: Denosumab fracture Intervention RandomizEd placebo Controlled Trial (DIRECT) (J Clin Endocrinol Metab)
04/08/2014 Established and forthcoming drugs for the treatment of osteoporosis (Curr Opin Rheumatol)
04/03/2014 Use of strontium ranelate and risk of acute coronary syndrome: cohort study (Ann Rheum Dis)
04/01/2014 Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis (J Clin Pharm Ther)
03/27/2014 External auditory canal and middle ear cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients: a Danish national register-based cohort study and literature review (Osteoporos Int)
03/27/2014 Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy (Rheumatol Int)
03/26/2014 The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab (Gynecol Endocrinol)
03/24/2014 Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis (Menopause)
03/20/2014 Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate (Clin Rheumatol)
03/10/2014 Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss (Osteoporos Int)
03/10/2014 Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study (Osteoporos Int)
03/10/2014 Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis (Osteoporos Int)
03/07/2014 Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population (Osteoporos Int)


 1  2  3     Next


Copyright © 2015, NTK Institute |  Terms and Conditions  |  Privacy Policy